{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:57:30Z","timestamp":1792616250270,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007856","name":"Baylor College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA125123"],"award-info":[{"award-number":["P30CA125123"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jtct.2023.10.024","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T05:03:47Z","timestamp":1699074227000},"page":"217-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"30","author":[{"given":"Gabriela","family":"Llaurador","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9014-7538","authenticated-orcid":false,"given":"Kristen","family":"Shaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Gillispie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5212-8490","authenticated-orcid":false,"given":"Anil","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-3167","authenticated-orcid":false,"given":"David","family":"Steffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Krance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caridad","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-7698","authenticated-orcid":false,"given":"Helen","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baheyeldin","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.10.024_bib0001","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.024_bib0002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-020-00342-x","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study","volume":"10","author":"Locatelli","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jtct.2023.10.024_bib0003","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2023.10.024_bib0004","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2023.10.024_bib0005","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jama.2021.1395","article-title":"Blinatumomab for treatment of children with high-risk relapsed B-cell acute lymphoblastic leukemia","volume":"325","author":"Shukla","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2023.10.024_bib0006","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bbmt.2020.01.029","article-title":"Outcomes of allogeneic hematopoietic cell transplantation after salvage therapy with blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"26","author":"Salhotra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.10.024_bib0007","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/s41409-021-01279-w","article-title":"Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data","volume":"56","author":"Badar","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.10.024_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2020.12.020","article-title":"Allogeneic hematopoietic cell transplantation for relapsed and refractory Philadelphia negative B cell ALL in the era of novel salvage therapies","volume":"27","author":"Aldoss","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1 suppl","key":"10.1016\/j.jtct.2023.10.024_bib0009","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbmt.2008.11.009","article-title":"Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease\/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse","volume":"15","author":"Pulsipher","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.10.024_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjh.12358","article-title":"Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation","volume":"162","author":"Campana","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.10.024_bib0011","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/leu.2016.234","article-title":"Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy","volume":"31","author":"Pui","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.024_bib0012","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/jcm6070066","article-title":"When less is good, is none better? The prognostic and therapeutic significance of peri-transplant minimal residual disease assessment in pediatric acute lymphoblastic leukemia","volume":"6","author":"Lamble","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtct.2023.10.024_bib0013","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","article-title":"Survival after blinatumomab treatment in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Gore","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jtct.2023.10.024_bib0014","doi-asserted-by":"crossref","first-page":"e29562","DOI":"10.1002\/pbc.29562","article-title":"Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: results from the NEUF study","volume":"69","author":"Locatelli","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.10.024_bib0015","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1182\/bloodadvances.2018025726","article-title":"Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia","volume":"3","author":"Keating","year":"2019","journal-title":"Blood Adv."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723016470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723016470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:13:32Z","timestamp":1763003612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723016470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2666636723016470"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.10.024","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}